insights_auto
Why is EVGN down 3.14%?
Dive Deeperchevron_right
EVGN:NASDAQ
Evogene Ltd
$0.36
arrow_downward
-3.14%(-0.012) 1D
$0.36
arrow_downward
-1.13% (-0.0041)bedtimeAfter hours
Closed: Oct 23, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EVGN...
Open
$0.37
High
$0.37
Low
$0.36
Mkt. cap
4.95M
Avg. vol.
2.56M
Volume
9.40K
52-wk high
$1.33
52-wk low
$0.35
EPS
-$0.90
Beta
1.44
Shares outstanding
18.05M
No. of employees
52
Open
$0.37
High
$0.37
Low
$0.36
Mkt. cap
4.95M
Avg. vol.
2.56M
Volume
9.40K
52-wk high
$1.33
52-wk low
$0.35
EPS
-$0.90
Beta
1.44
Shares outstanding
18.05M
No. of employees
52
News stories
From web sources and news partners
Cassandra Unchained | Michael Burry
·
15 hours ago
Foundations: The Fate of the S&P 500’s Worst Stocks, the Y2K Analogue, and Time for Small Caps?
Yardeni QuickTakes
·
8 hours ago
US MARKETS CALL: Still Proceeding Cautiously
Investor's Business Daily
·
7 hours ago
What To Do In A Doom-And-Bloom Market; 3 Titans Loom
Profile
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
About Evogene Ltd